You just read:

BiondVax Appoints CRO to Conduct Pivotal Clinical Efficacy Phase 3 Trial of Its Novel Universal Flu Vaccine Candidate

News provided by

BiondVax Pharmaceuticals Ltd.

13 Jan, 2016, 13:00 GMT